Literature DB >> 36030347

Sex, gender, and subclinical hypertensiveorgan damage-heart.

Cesare Cuspidi1, Elisa Gherbesi2, Carla Sala2, Marijana Tadic3.   

Abstract

Hypertension-mediated organ damage (HMOD) at cardiac level include a variety of abnormal phenotypes of recognized adverse prognostic value. Although the risk of cardiac HMOD is related with the severity of BP elevation, the interaction of numerous non-hemodynamic factors plays a relevant role in this unfavorable dynamic process. In particular, sex-related differences in cardiovascular (CV) risk factors and HMOD have been increasingly described. The objective of the present review is to provide comprehensive, updated information on sex-related differences in cardiac HMOD, focusing on the most important manifestations of subclinical hypertensive heart disease such as left ventricular hypertrophy (LVH), LV systolic and diastolic dysfunction, left atrial and aortic dilatation. Current evidence, based on cross-sectional and longitudinal observational studies as well as real-world registries and randomized controlled trials, suggests that women are more at risk of developing (and maintaining) LVH, concentric remodeling and subclinical LV dysfunction, namely the morpho-functional features of heart failure with preserved ejection fraction. It should be pointed out, however, that further studies are needed to fill the gap in defining gender-based optimal therapeutic strategies in order to protect women's hearts.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 36030347     DOI: 10.1038/s41371-022-00750-5

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   2.877


  75 in total

1.  LV Mass as a Predictor of CVD Events in Older Adults With and Without Metabolic Syndrome and Diabetes.

Authors:  Khiet Hoang; Yanglu Zhao; Julius M Gardin; Mercedes Carnethon; Ken Mukamal; David Yanez; Nathan D Wong
Journal:  JACC Cardiovasc Imaging       Date:  2015-08-26

2.  Home versus office blood pressure: longitudinal relations with left ventricular hypertrophy: the Finn-Home study.

Authors:  Sam S E Sivén; Teemu J Niiranen; Ville L J Langén; Pauli J Puukka; Ilkka M Kantola; Antti M Jula
Journal:  J Hypertens       Date:  2017-02       Impact factor: 4.844

3.  Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation.

Authors:  G Mancia; A Zanchetti; E Agabiti-Rosei; G Benemio; R De Cesaris; R Fogari; A Pessina; C Porcellati; A Rappelli; A Salvetti; B Trimarco; E Agebiti-Rosei; A Pessino
Journal:  Circulation       Date:  1997-03-18       Impact factor: 29.690

4.  Aortic Root Dilatation in Hypertensive Patients with Left Ventricular Hypertrophy-Application of A New Multivariate Predictive Model. The Life Study.

Authors:  Alexander Lilja-Cyron; Casper N Bang; Eva Gerdts; Anne C Larstorp; Sverre E Kjeldsen; Stevo Julius; Peter M Okin; Kristian Wachtell; Richard B Devereux
Journal:  Rev Cardiovasc Med       Date:  2022-03-10       Impact factor: 2.930

5.  Left ventricular and atrial remodelling in hypertensive patients using thresholds from international guidelines and EMINCA data.

Authors:  Yuanyuan Sheng; Mengmeng Li; Mingjun Xu; Yu Zhang; Jinfeng Xu; Yuxiang Huang; Xiaoyi Li; Guihua Yao; Wenhai Sui; Meng Zhang; Yuan Zhang; Cheng Zhang; Yun Zhang; Mei Zhang
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2022-01-24       Impact factor: 6.875

6.  Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension.

Authors:  Sante D Pierdomenico; Domenico Lapenna; Franco Cuccurullo
Journal:  Am J Hypertens       Date:  2008-02-07       Impact factor: 2.689

7.  2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension.

Authors:  Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis Clement; Antonio Coca; Giovanni De Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland Schmieder; Evgeny Shlyakhto; Konstantinos Tsioufis; Victor Aboyans; Ileana Desormais
Journal:  J Hypertens       Date:  2018-12       Impact factor: 4.844

8.  Prognostic significance of left ventricular mass change during treatment of hypertension.

Authors:  Richard B Devereux; Kristian Wachtell; Eva Gerdts; Kurt Boman; Markku S Nieminen; Vasilios Papademetriou; Jens Rokkedal; Katherine Harris; Peter Aurup; Björn Dahlöf
Journal:  JAMA       Date:  2004-11-17       Impact factor: 56.272

9.  The remodelling index risk stratifies patients with hypertensive left ventricular hypertrophy.

Authors:  Thu-Thao Le; Vanessa Lim; Rositaa Ibrahim; Muh-Tyng Teo; Jennifer Bryant; Briana Ang; Boyang Su; Tar-Choon Aw; Chi-Hang Lee; Jeroen Bax; Stuart Cook; Calvin W L Chin
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-05-10       Impact factor: 6.875

10.  Blood pressure categorization and subclinical left ventricular dysfunction in antihypertensive medication-naive subjects.

Authors:  Koki Nakanishi; Masao Daimon; Yuriko Yoshida; Jumpei Ishiwata; Naoko Sawada; Megumi Hirokawa; Hidehiro Kaneko; Tomoko Nakao; Yoshiko Mizuno; Hiroyuki Morita; Marco R Di Tullio; Shunichi Homma; Issei Komuro
Journal:  ESC Heart Fail       Date:  2022-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.